Funding Round
Alto Neuroscience raises $120M Series D ahead of CANOPY Phase 3 PTSD trial
STAT News3/26/2026·03/26/26🌐 USA
Summary
Alto Neuroscience secured $120M Series D led by General Atlantic, with Novo Holdings, Lux Capital, and Andreessen Horowitz Bio, ahead of their 600-patient Phase 3 CANOPY trial for ALTO-300 in PTSD. The round is the largest in Alto's history and one of the largest precision psychiatry raises ever. Total funding now exceeds $280M.
Why it matters
A $120M Series D for a Phase 3 psychiatric drug company is a significant vote of confidence. General Atlantic leading — a growth equity investor that rarely backs pre-NDA biotech — signals that Alto's PTSD Phase 2 data was compelling enough to attract commercial-stage capital. This round provides runway through NDA filing.
#Industry#Neuropharmacology#Neurostimulation#PTSD#Phase 3#USA#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in